"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial"

"Background Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18...

Descripción completa

Detalles Bibliográficos
Autores Principales: "Huh, Warner K, Joura, Elmar A, Giuliano, Anna R, Iversen, Ole-Erik, de Andrade, Rosires Pereira, Ault, Kevin A, Bartholomew, Deborah, Cestero, Ramon M, Fedrizzi, Edison N, Hirschberg, Angelica L, Mayrand, Marie-Hélène, Ruiz-Sternberg, Angela Maria, Stapleton, Jack T, Wiley, Dorothy J, Ferenczy, Alex, Kurman, Robert, Ronnett, Brigitte M, Stoler, Mark H, Cuzick, Jack, Garland, Suzanne M, Kjaer, Susanne K, Bautista, Oliver M, Haupt, Richard, Moeller, Erin, Ritter, Michael, Roberts, Christine C, Shields, Christine, Luxembourg, Alain"
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Lancet Publishing Group 2017
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/23374
https://doi.org/10.1016/S0140-6736(17)31821-4